PRIMARY TREATMENT OF INCOMPLETE KAWASAKI DISEASE WITH INFLIXIMAB AND METHYLPREDNISOLONE IN A PATIENT WITH A CONTRAINDICATION TO INTRAVENOUS IMMUNE GLOBULIN
Authors:
- Debbie-Ann ShirleyDSDebbie-Ann Shirley
- Ina StephensISIna Stephens
- 1 October 2010
- journal article
- case report
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 29 (10) , 978-979
Abstract
Incomplete Kawasaki disease was diagnosed in a 3-year-old boy. Because intravenous immune globulin infusion was not tolerated, he was treated with infliximab and methylprednisolone. Coronary aneurysms were not visualized on initial or follow-up echocardiograms. To our knowledge, this is the first report to document the use of infliximab and methylprednisolone as first line therapy for Kawasaki disease.Keywords
This publication has 16 references indexed in Scilit:
- Treatment of Kawasaki Disease: Analysis of 27 US Pediatric Hospitals From 2001 to 2006Pediatrics, 2009
- Infliximab Treatment of Intravenous Immunoglobulin–Resistant Kawasaki DiseaseThe Journal of Pediatrics, 2008
- Randomized Trial of Pulsed Corticosteroid Therapy for Primary Treatment of Kawasaki DiseaseNew England Journal of Medicine, 2007
- A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: Clinical course and coronary artery outcomeThe Journal of Pediatrics, 2006
- Pulse steroids: How much is enough?Autoimmunity Reviews, 2006
- Infliximab treatment for refractory Kawasaki syndromeThe Journal of Pediatrics, 2005
- Kawasaki diseaseCurrent Opinion in Pediatrics, 2004
- Long-term Consequences of Kawasaki DiseaseCirculation, 1996
- Peripheral blood monocyte/macrophages and serum tumor necrosis factor in Kawasaki diseaseClinical Immunology and Immunopathology, 1988
- The Treatment of Kawasaki Syndrome with Intravenous Gamma GlobulinNew England Journal of Medicine, 1986